Restoring tissue regeneration in patients with visceral Graft versus Host Disease.
RETHRIM is a research consortium interested in the potential use of MSC to treat GvHD
RETHRIM combines experts in the field of hematology, regenerative medicine and assay development
RETHRIM will conduct a clinical trial and develop predictive assays for patient eligibility and MSC potency
RETHRIM is an EU sponsored research consortium that has initiated a phase III clinical trial to investigate the usefulness of Mesenchymal Stromal Cells for the treatment of Graft-versus-Host-Disease
RETHRIM receives funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643580